Aripra

Aripen is indicated for-
Schizophrenia
Bipolar disorder
Adjunctive treatment of major depressive disorder
Irritability associated with autistic disorder
Agitation associated with schizophrenia or bipolar mania

Vomiting, nausea, akathisia, extrapyramidal disorder, somnolence, sedation, dizziness, insomnia, tremor, restlessness, fatigue, blurred vision, salivary hypersecretion, constipation, pyrexia, drooling, decreased appetite.

Elderly Patients with Dementia-Related Psychosis
: Increased incidence of cerebrovascular adverse events (eg, stroke, transient ischemic attack, including fatalities).
Suicidality & antidepressants
: Increased risk of suicidality in children, adolescents, young and adults with major depressive disorder.
Tardive dyskinesia
: Discontinue if clinically appropriate.
Metabolic changes
: Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain.
Orthostatic hypotension
: Use with caution in patients with known cardiovascular or cerebrovascular disease.
Seizures/Convulsions
: Use cautiously in patients with a history of seizures.
Use caution when operating machinery.

Aripiprazole is an atypical antipsychotic and it has been proposed that the efficacy of Aripiprazole is mediated through a combination of partial agonist activity at Dopamine D2 and Serotonin 5-HT 1A receptors and antagonist activity at Serotonin 5-HT 2A receptors. This is associated with improvement of schizophrenia, bipolar disorder, major depressive disorder, irritability associated with autistic disorder, and agitation associated with schizophrenia or bipolar disorder.